AXATILIMAB
SNDX-6352-0504
Phase 2 small_molecule active
Quick answer
AXATILIMAB for Chronic graft versus host disease (cGVHD) is a Phase 2 program (small_molecule) at Syndax Pharmaceuticals Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Syndax Pharmaceuticals Inc
- Indication
- Chronic graft versus host disease (cGVHD)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active